Biogen Stock Forecast, Price & News

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 sell ratings, 14 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Biogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
View analyst ratings for Biogen or view top-rated stocks.

Wall Street analysts have given Biogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Biogen is scheduled to release its next quarterly earnings announcement on Thursday, April 22nd 2021.
View our earnings forecast for Biogen.

Biogen will be holding an earnings conference call on Thursday, April 22nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Biogen Inc. (NASDAQ:BIIB) issued its earnings results on Tuesday, February, 2nd. The biotechnology company reported $4.58 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $4.87 by $0.29. The biotechnology company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.80 billion. Biogen had a trailing twelve-month return on equity of 51.00% and a net margin of 35.63%. The firm's revenue for the quarter was down 22.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.34 EPS.
View Biogen's earnings history.

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BIIB stock has decreased by 10.2% and is now trading at $264.26.
View which stocks have been most impacted by COVID-19.

Biogen announced that its Board of Directors has authorized a stock repurchase plan on Monday, December 23rd 2019, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company's management believes its stock is undervalued.

Biogen issued an update on its FY 2021 Pre-Market earnings guidance on Wednesday, February, 3rd. The company provided earnings per share guidance of 17.00-18.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $24.67. The company issued revenue guidance of $10.45-10.75 billion, compared to the consensus revenue estimate of $11.22 billion.

31 Wall Street analysts have issued 1 year price objectives for Biogen's stock. Their forecasts range from $175.00 to $450.00. On average, they anticipate Biogen's stock price to reach $303.59 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price.
View analysts' price targets for Biogen or view top-rated stocks among Wall Street analysts.

186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among Biogen's employees.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of BIIB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by a number of institutional and retail investors. Top institutional investors include Saratoga Research & Investment Management (0.17%), Royal London Asset Management Ltd. (0.08%), State of Alaska Department of Revenue (0.04%), Pacer Advisors Inc. (0.02%), Calamos Advisors LLC (0.02%) and Hexavest Inc. (0.02%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michel Vounatsos and Stephen A Sherwin.
View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., State of Alaska Department of Revenue, OLD Dominion Capital Management Inc., Thomasville National Bank, CHICAGO TRUST Co NA, Pensionfund Sabic, Triangle Securities Wealth Management, and American Research & Management Co..
View insider buying and selling activity for Biogen or view top insider-selling stocks.

BIIB stock was bought by a variety of institutional investors in the last quarter, including Saratoga Research & Investment Management, Royal London Asset Management Ltd., Everence Capital Management Inc., Pacer Advisors Inc., Calamos Advisors LLC, Pensionfund DSM Netherlands, Carroll Financial Associates Inc., and KMG Fiduciary Partners LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen or or view top insider-buying stocks.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIIB stock can currently be purchased for approximately $264.26.

Biogen has a market capitalization of $40.26 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis.

Biogen employs 9,100 workers across the globe.

The following companies are subsidiares of Biogen: AliveGen, Biogen (Argentina) SRL, Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (Denmark) Manufacturing ApS, Biogen (Denmark) New Manufacturing ApS, Biogen (RTP) Realty LLC, Biogen (Singapore) Pte Ltd, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd., Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Colombia S.A.S., Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding APS, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Hong Kong Limited, Biogen Idec Ltd., Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia SRL, Biogen Japan Ltd., Biogen Korea, Biogen Luxembourg Holding SARL, Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen Mexico Servicios S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o, Biogen Poland Sp. z.o.o, Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Ltd., Eidetica Biopharma GmbH, Fumapharm, Karyopharm Therapeutics, Nightstar Europa Limited, Nightstar Inc., Nightstar Limited, Nightstar Therapeutics, Nightstar Therapeutics Limited, Old Convergence Pharmaceuticals Ltd., Panion Ltd., Remedy Pharmaceuticals, Silver Acquisition Co. Ltd., Stromedix, Stromedix Inc., Syntonix Pharmaceuticals, Tungsten Bidco Limited, and Tysabri.

Biogen was founded in 1978.

The official website for Biogen is www.biogen.com.

Biogen is headquartered at 225 BINNEY STREET, CAMBRIDGE MA, 02142.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]